Erratum: 14,15-epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates: Carboxylate modifications (Journal of Medicinal Chemistry (2014) 57 (6965-6972) DOI: 10.1021/jm500262m);14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates: Carboxylate modifications

Journal of Medicinal Chemistry

Volumn 57, Issue 16, 2014, Pages 6965-6972

  Falck, John R ^a   Koduru, Sreenivasulu Reddy ^a   Mohapatra, Seetaram ^a   Manne, Rajkumar ^a   Atcha, Raju ^a   Manthati, Vijaya L ^a   Capdevila, Jorge H ^b   Christian, Sarah ^c   Imig, John D ^c   Campbell, William B ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (12 BROMODODEC 5 ENYL) 3 N PENTYLUREA; 1 (12 CYANODODEC 5 ENYL) 3 N PENTYLUREA; 1 (12 HYDROXYDODEC 5 ENYL) 3 N PENTYLUREA; 1 TERT BUTYLDIPHENYLSILYLOXY 12 AMINODODEC 7 ENE; 1 TERT BUTYLDIPHENYLSILYLOXY 12 AZIDODODEC 7 ENE; 1 [12 (1H TETRAZOL 5 YL)DODEC 5 EN 1 YL] 3 PENTYLUREA; 1 [12 (TERT BUTYLDIPHENYLSILYLOXY)DODEC 5 ENYL] 3 N PENTYLUREA; 12 (TERT BUTYLDIPHENYLSILYLOXY)DODEC 5 EN 1 OL; 14,15 EPOXYEICOSA 5,8,11 TRIENOIC ACID DERIVATIVE; AUTACOID; CARBOXYLIC ACID; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; ICOSANOID; N 1 (12 BROMODODEC 5 ENYL) N 2 N BUTYLOXALAMIDE; N 1 BUTYL N 2 [12 (2 OXIDO 3H 1,2,3,5 OXATHIADIAZOL 4 YL)DODEC 5 EN 1 YL]OXALAMIDE; N 1 N BUTYL N 2 (12 CYANODODEC 5 ENYL)OXALAMIDE; N 1 N BUTYL N 2 (12 HYDROXYDODEC 5 ENYL)OXALAMIDE; N 1 N BUTYL N 2 [12 (TERT BUTYLDIPHENYLSILYLOXY)DODEC 5 ENYL]OXALAMIDE; N 1 [13 AMINO 13 (HYDROXYIMINO)TRIDEC 5 ENYL] N 2 N BUTYLOXALAMIDE; UNCLASSIFIED DRUG; VASODILATOR AGENT; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; 1H-TETRAZOLE; DIHOMO GAMMA LINOLENIC ACID; ENZYME INHIBITOR; N1-BUTYL-N2-(12-(2-OXIDO-3H-1,2,3,5-OXATHIADIAZOL-4-YL)DODEC-5-EN-1-YL)OXALAMIDE; OXADIAZOLE DERIVATIVE; OXAMIC ACID; TETRAZOLE DERIVATIVE;

ACIDITY; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; DRUG POTENCY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MEDIAN EFFECTIVE CONCENTRATION; NONHUMAN; OXIDATION; PKA; VASODILATATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BOVINE; CHEMISTRY; CORONARY BLOOD VESSEL; DRUG EFFECTS; HUMAN; MOLECULAR MIMICRY; SYNTHESIS;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; CATTLE; CHEMISTRY TECHNIQUES, SYNTHETIC; CORONARY VESSELS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; IN VITRO TECHNIQUES; MOLECULAR MIMICRY; OXADIAZOLES; OXAMIC ACID; TETRAZOLES; VASODILATION; VASODILATOR AGENTS;

EID: 84906871712     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5016457     Document Type: Erratum

References (63)

1. Review: Bellien, J.; Joannides, R. Epoxyeicosatrienoic Acid Pathway in Human Health and Diseases J. Cardiovasc. Pharmacol. 2013, 61, 188-196
2. Review: Pfister, S. L.; Gauthier, K. M.; Campbell, W. B. Vascular Pharmacology of Epoxyeicosatrienoic Acids Adv. Pharmacol. 2010, 60, 27-59
3. Terashvili, M.; Tseng, L. F.; Wu, H. E.; Narayanan, J.; Hart, L. M.; Falck, J. R.; Pratt, P. F.; Harder, D. R. Antinociception Produced by 14,15-Epoxyeicosatrienoic Acid is Mediated by the Activation of Beta-Endorphin and Met-Enkephalin in the Rat Ventrolateral Periaqueductal Gray J. Pharmacol. Exp. Ther. 2008, 326, 614-622
4. Sisignano, M.; Park, C. K.; Angioni, C.; Zhang, D. D.; von Hehn, C.; Cobos, E. J.; Ghasemlou, N.; Xu, Z. Z.; Kumaran, V.; Lu, R.; Grant, A.; Fischer, M. J.; Schmidtko, A.; Reeh, P.; Ji, R. R.; Woolf, C. J.; Geisslinger, G.; Scholich, K.; Brenneis, C. 5,6-EET is Released Upon Neuronal Activity and Induces Mechanical Pain Hypersensitivity via TRPA1 on Central Afferent Terminals J. Neurosci. 2012, 32, 6364-6372
5. Conroy, J. L.; Fang, C.; Gu, J.; Zeitlin, S. O.; Yang, W.; Yang, J.; VanAlstine, M. A.; Nalwalk, J. W.; Albrecht, P. J.; Mazurkiewicz, J. E.; Snyder-Keller, A.; Shan, Z.; Zhang, S.-Z.; Wentland, M. P.; Behr, M.; Knapp, B. I.; Bidlack, J. M.; Zuiderveld, O. P.; Leurs, R.; Ding, X.; Hough, L. B. Opioids Activate Brain Analgesic Circuits Through Cytochrome P450/Epoxygenase Signaling Nature Neurosci. 2010, 13, 284-286
6. Inceoglu, B.; Jinks, S. L.; Ulu, A.; Hegedus, C. M.; Georgi, K.; Schmelzer, K. R.; Wagner, K.; Jones, P. D.; Morisseau, C.; Hammock, B. D. Soluble Epoxide Hydrolase and Epoxyeicosatrienoic Acids Modulate Two Distinct Analgesic Pathways Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 18901-18906
7. Burgess, A. P.; Vanella, L.; Bellner, L.; Gotlinger, K.; Falck, J. R.; Abraham, N. G.; Schwartzman, M. L.; Kappas, A. Heme Oxygenase (HO-1) Rescue of Adipocyte Dysfunction in HO-2 Deficient Mice via Recruitment of Epoxyeicosatrienoic Acids (EETs) and Adiponectin Cell Physiol. Biochem. 2012, 29, 99-110
8. Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. C.; Liao, J. K. Anti-Inflammatory Properties of Cytochrome P450 Epoxygenase-Derived Eicosanoids Science 1999, 285, 1276-1279
9. Deng, Y.; Theken, K. N.; Lee, C. R. Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and the Regulation of Cardiovascular Inflammation J. Mol. Cell. Cardiol. 2010, 48, 331-341
10. Panigrahy, D.; Kalish, B. T.; Huang, S.; Bielenberg, D. R.; Le, H. D.; Yang, J.; Edin, M. L.; Lee, C. R.; Benny, O.; Mudge, D. K.; Butterfield, C. E.; Mammoto, A.; Mammoto, T.; Inceoglu, B.; Jenkins, R. L.; Simpson, M. A.; Akino, T.; Lih, F. B.; Tomer, K. B.; Ingber, D. E.; Hammock, B. D.; Falck, J. R.; Manthati, V. L.; Kaipainen, A.; D'Amore, P. A.; Puder, M.; Zeldin, D. C.; Kieran, M. W. Epoxyeicosanoids Promote Organ and Tissue Regeneration Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 13528-13533
11. Skepner, J. E.; Shelly, L. D.; Ji, C.; Reidich, B.; Luo, Y. Chronic Treatment with Epoxyeicosatrienoic Acids Modulates Insulin Signaling and Prevents insulin Resistance in Hepatocytes Prostaglandins Other Lipid Mediat. 2011, 94, 3-8
12. Sharma, M.; McCarthy, E. T.; Reddy, D. S.; Patel, P. K.; Savin, V. J.; Medhora, M.; Falck, J. R. 8,9-Epoxyeicosatrienoic Acid Protects the Glomerular Filtration Barrier Prostaglandins Other Lipid Mediat. 2009, 89, 43-51
13. Stables, M. J.; Gilroy, D. W. Old and New Generation Lipid Mediators in Acute Inflammation and Resolution Prog. Lipid Res. 2011, 50, 35-51
14. Yaghi, A.; Bradbury, J. A.; Zeldin, D. C.; Mehta, S.; Bend, J. R.; McCormack, D. G. Pulmonary Cytochrome P-450 2J4 is Reduced in a Rat Model of Acute Pseudomonas pneumonia Am. J. Physiol. 2003, 285, L1099-L1105
15. Karara, A.; Wei, S.; Spady, D.; Swift, L.; Capdevila, J. H.; Falck, J. R. Arachidonic Acid Epoxygenase: Structural Characterization and Quantification of Epoxyeicosatrienoates in Plasma Biochem. Biophys. Res. Commun. 1992, 182, 1320-1325
16. Zhu, Y.; Schieber, E. B.; McGiff, J. C.; Balazy, M. Identification of Arachidonate P-450 Metabolites in Human Platelet Phospholipids Hypertension 1995, 25, 854-859
17. Daikh, B. E.; Lasker, J. M.; Raucy, J. L.; Koop, D. R. Regio- and Stereoselective Epoxidation of Arachidonic Acid by Human Cytochromes P450 2C8 and 2C9 J. Pharmacol. Exp. Ther. 1994, 271, 1427-1433
18. Wu, S.; Moomaw, C. R.; Tomer, K. B.; Falck, J. R.; Zeldin, D. C. Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in Heart J. Biol. Chem. 1996, 271, 3460-3468
19. Capdevila, J. H.; Falck, J. R. Biochemical and Molecular Properties of the Cytochrome P450 Arachidonic Acid Monooxygenases Prostaglandins Other Lipid Mediators 2002, 68-69, 325-344
20. Capdevila, J. H.; Falck, J. R.; Harris, R. C. Cytochrome P450 and Arachidonic Acid Bioactivation. Molecular and Functional Properties of the Arachidonate Monooxygenase J. Lipid Res. 2000, 41, 163-181
21. Falck, J. R.; Kodela, R.; Manne, R.; Atcha, K. R.; Puli, N.; Dubasi, N.; Manthati, V. L.; Capdevila, J. H.; Yi, X.-Y.; Goldman, D. H.; Morisseau, C.; Hammock, B. D.; Campbell, W. B. 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) Surrogates Containing Epoxide Bioisosteres: Influence upon Vascular Relaxation and Soluble Hydrolase Inhibition J. Med. Chem. 2009, 52, 5069-5075
22. Yin, H.; Porter, N. A. New Insights Regarding the Autoxidation of Polyunsaturated Fatty Acids Antioxid. Redox Signaling 2005, 7, 170-184
23. Fang, X.; Weintraub, N. L.; Spector, A. A. Differences in Positional Esterification of 14,15-Epoxyeicosatrienoic Acid in Phosphatidylcholine of Porcine Coronary Artery Endothelial and Smooth Muscle Cells Prostaglandins Other Lipid Mediators 2003, 71, 33-42
24. Capdevila, J. H.; Mosset, P.; Yadagiri, P.; Lumin, S.; Falck, J. R. NADPH-Dependent Microsomal Metabolism of 14,15-Epoxyeicosatrienoic Acid to Diepoxides and Epoxyalcohols Arch. Biochem. Biophys. 1988, 261, 122-133
25. le Quere, V.; Plee-Gautier, E.; Potin, P.; Madec, S.; Salauen, J.-P. Human CYP4F3s are the Main Catalysts in the Oxidation of Fatty Acid Epoxides J. Lipid Res. 2004, 45, 1446-1458
26. Homma, T.; Zhang, J. Y.; Shimizu, T.; Prakash, C.; Blair, I. A.; Harris, R. C. Cyclooxygenase-Derived Metabolites of 8,9-Epoxyeicosatrienoic Acid are Potent Mitogens for Cultured Rat Glomerular Mesangial Cells Biochem. Biophys. Res. Commun. 1993, 191, 282-288
27. Spearman, M. E.; Prough, R. A.; Estabrook, R. W.; Falck, J. R.; Manna, S.; Leibman, K. C.; Murphy, R. C.; Capdevila, J. Novel Glutathione Conjugates Formed from Epoxyeicosatrienoic Acids (EETs) Arch. Biochem. Biophys. 1985, 242, 225-230
28. Fang, X.; Weintraub, N. L.; Oltman, C. L.; Stoll, L. L.; Kaduce, T. L.; Harmon, S.; Dellsperger, K. C.; Morisseau, C.; Hammock, B. D.; Spector, A. A. Human Coronary Endothelial Cells Convert 14,15-EET to a Biologically Active Chain-Shortened Epoxide Am. J. Physiol. 2002, 283, H2306-H2314
29. Fang, X.; Kaduce, T. L.; Weintraub, N. L.; Harmon, S.; Teesch, L. M.; Morisseau, C.; Thompson, D. A.; Hammock, B. D.; Spector, A. A. Pathways of Epoxyeicosatrienoic Acid Metabolism in Endothelial Cells. Implications for the Vascular Effects of Soluble Epoxide Hydrolase Inhibition J. Biol. Chem. 2001, 276, 14867-14874
30. Chacos, N.; Capdevila, J.; Falck, J. R.; Manna, S.; Martin-Wixtrom, C.; Gill, S. S.; Hammock, B. D.; Estabrook, R. W. The Reaction of Arachidonic Acid Epoxides (Epoxyeicosatrienoic Acids) with a Cytosolic Epoxide Hydrolase Arch. Biochem. Biophys. 1983, 223, 639-648
31. Kim, I.-H.; Heirtzler, F. R.; Morisseau, C.; Nishi, K.; Tsai, H.-J.; Hammock, B. D. Optimization of Amide-Based Inhibitors of Soluble Epoxide Hydrolase with Improved Water Solubility J. Med. Chem. 2005, 48, 3621-3629
32. Catella, F.; Lawson, J. A.; Fitzgerald, D. J.; FitzGerald, G. A. Endogenous Biosynthesis of Arachidonic Acid Epoxides in Humans: Increased Formation in Pregnancy-Induced Hypertension Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 5893-5897
33. Kim, I.-H.; Nishi, K.; Tsai, H.-J; Bradford, T.; Koda, Y.; Watanabe, T.; Morisseau, C.; Blanchfield, J.; Toth, I.; Hammock, B. D. Design of Bioavailable Derivatives of 12-(3-Adamantan-1-yl-ureido)dodecanoic acid, a Potent Inhibitor of the Soluble Epoxide Hydrolase Bioorg. Med. Chem. 2007, 15, 312-323
34. Shen, H. C.; Ding, F.-X.; Deng, Q.; Xu, S.; Chen, H.-s.; Tong, X.; Tong, V.; Zhang, X.; Chen, Y.; Zhou, G.; Pai, L.-Y.; Alonso-Galicia, M.; Zhang, B.; Roy, S.; Tata, J. R.; Berger, J. P.; Colletti, S. L. Discovery of 3,3-Disubstituted Piperidine-Derived Trisubstituted Ureas as Highly Potent Soluble Epoxide Hydrolase Inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5314-5320
35. Yaghi, A.; Bradbury, J. A.; Zeldin, D. C.; Mehta, S.; Bend, J. R.; McCormack, D. G. Pulmonary Cytochrome P-450 2J4 is Reduced in a Rat Model of Acute Pseudomonas pneumonia Am. J. Physiol. 2003, 285, L1099-1105
36. Sodhi, K.; Inoue, K.; Gotlinger, K. H.; Canestraro, M.; Vanella, L.; Kim, D. H.; Manthati, V. L.; Koduru, S. R.; Falck, J. R.; Schwartzman, M. L.; Abraham, N. G. Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null Mice J. Pharmacol. Exp. Ther. 2009, 331, 906-916
37. Jiang, H.; McGiff, J. C.; Fava, C.; Amen, G.; Nesta, E.; Zanconato, G.; Quilley, J.; Minuz, P. Maternal and Fetal Epoxyeicosatrienoic Acids in Normotensive and Preeclamptic Pregnancies Am. J. Hypertens. 2013, 26, 271-278
38. Carroll, M. A. Role of the Adenosine(2A) Receptor-Epoxyeicosatrienoic Acid Pathway in the Development of Salt-Sensitive Hypertension Prostaglandins Other Lipid Mediators 2012, 98, 39-47
39. Luo, P.; Zhou, Y.; Chang, H. H.; Zhang, J.; Seki, T.; Wang, C. Y.; Inscho, E. W.; Wang, M. H. Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy Am. J. Physiol. 2009, 296, F556-563
40. Falck, J. R.; Krishna, U. M.; Reddy, Y. K.; Kumar, P. S.; Reddy, K. M.; Hittner, S. B.; Deeter, C.; Sharma, K.K.; Gauthier, K. M.; Campbell, W. B. Comparison of Vasodilatory Properties of 14,15-EET Analogs: Structural Requirements for Dilation Am. J. Physiol. 2003, 284, H337-H349
41. Gauthier, K. M.; Falck, J. R.; Reddy, L. M.; Campbell, W. B. 14,15-EET Analogs: Characterization of Structural Requirements for Agonist and Antagonist Activity in Bovine Coronary Arteries Pharm. Res. 2004, 49, 515-524
42. Yang, W.; Holmes, B. B.; Gopal, V. R.; Kishore, R. V. K.; Sangras, B.; Yi, X.-Y.; Falck, J. R.; Campbell, W. B. Characterization of 14,15-Epoxyeicosatrienoyl-sulfonamides as 14,15-Epoxyeicosatrienoic Acid Agonists: Use for Studies of Metabolism and Ligand Binding J. Pharm. Exp. Ther. 2007, 321, 1023-1031
43. Yang, W.; Gauthier, K. M.; Reddy, L. M.; Sangras, B.; Sharma, K. K.; Nithipatikom, K.; Falck, J. R.; Campbell, W. B. Stable 5,6-Epoxyeicosatrienoic Acid Analog Relaxes Coronary Arteries through Potassium Channel Activation Hypertension 2005, 45, 681-686
44. + Channels Contribute to 11,12-Epoxyeicosatrienoic Acid Analog Mediated Mesenteric Arterial Relaxation Prostaglandins Other Lipid Mediators 2007, 83, 50-61
45. + Channels Microcirculation 2008, 15, 137-150
46. Falck, J. R.; Reddy, L. M.; Reddy, Y. K.; Bondlela, M.; Krishna, U. M.; Ji, Y.; Sun, J.; Liao, J. K. 11,12-Epoxyeicosatrienoic Acid (11,12-EET): Structural Determinants for Inhibition of TNF-α-Induced VCAM-1 Expression Bioorg. Med. Chem. Lett. 2003, 13, 4011-4014
47. Imig, J. D.; Elmarakby, A.; Nithipatikom, K.; Wei, S.; Capdevila, J. H.; Tuniki, V. R.; Sangras, B.; Anjaiah, S.; Manthati, V. L.; Reddy, D. S.; Falck, J. R. Development of Epoxyeicosatrienoic Acid Analogs with in vivo Anti-Hypertensive Actions Front. Physiol. 2010, 1, 1-8 Article 157
48. Khan, Md. A. H.; Neckář, J.; Manthati, V.; Errabelli, R.; Pavlov, T. S.; Staruschenko, A.; Falck, J. R.; Imig, J. D. Orally Active Epoxyeicosatrienoic Acid Analog Attenuates Kidney Injury in Hypertensive Dahl Salt-Sensitive Rat Hypertension 2013, 62, 905-913
49. Barillari, C.; Brown, N. Classical Bioisosteres. In Bioisosteres in Medicinal Chemistry; Brown, N., Ed.; Wiley-VCH Verlag: Singapore, 2012; pp 15-27.
50. Batista, J.; Schlechtingen, G.; Friedrichson, T.; Braxmeier, T.; Bajorath, J. Lipid-Like Sulfoxides and Amine Oxides as Inhibitors of Mast Cell Activation Eur. J. Med. Chem. 2011, 46, 2147-2151
51. Herr, R. J. 5-Substituted-1 H -tetrazoles as Carboxylic Acid Isosteres: Medicinal Chemistry and Synthetic Methods Bioorg. Med. Chem. 2002, 10, 3379-3393
52. Kohara, Y.; Kubo, K.; Imamiya, E.; Wada, T.; Inada, Y.; Naka, T. Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres J. Med. Chem. 1996, 39, 5228-5235
53. Kohara, Y.; Kubo, K.; Imamiya, E.; Naka, T. A Facile Synthesis of 3-Substituted 5-Oxo-1,2,4-thiadiazoles from Amidoximes J. Heterocycl. Chem. 2000, 37, 1419-1423
54. Singh, J.; Mansoori, A. N.; Yadav, S.; Verma, S. A Review on 2,4-Thiazolidinedione in Type-2 Diabetes Adv. Res. Pharm. Biol. 2013, 3, 395-399
55. Tamayo, N.; Liao, H.; Stec, M. M.; Wang, X.; Chakrabarti, P.; Retz, D.; Doherty, E. M.; Surapaneni, S.; Tamir, R.; Bannon, A. W.; Gavva, N. R.; Norman, M. H. Design and Synthesis of Peripherally Restricted Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists J. Med. Chem. 2008, 51, 2744-2757
56. Yu, M.; Alonso-Galicia, M.; Sun, C.-W.; Roman, R. J.; Ono, N.; Hirano, H.; Ishimoto, T.; Reddy, Y. K.; Katipally, K. R.; Reddy, K. M.; Gopal, V. R.; Yu, J.; Takhi, M.; Falck, J. R. 20-Hydroxyeicosatetraenoic Acid (20-HETE): Structural Determinants for Renal Vasoconstriction Bioorg. Med. Chem. 2003, 11, 2803-2821
57. Demko, Z. P.; Sharpless, K. B. Preparation of 5-Substituted 1 H -Tetrazoles from Nitriles in Water J. Org. Chem. 2001, 66, 7945-7950
58. Oh, C.-H.; Lee, S.-C.; Jung-Hyuck Cho, J.-H. Synthesis and Antibacterial Activity of 1b-Methyl-2-[5(N -substituted-2-hydroxyiminoethyl)pyrrolidin-3- ylthio]carbapenem Derivatives Eur. J. Med. Chem. 2003, 38, 751-758
59. Gauthier, K. M.; Deeter, C.; Krishna, U. M.; Reddy, Y. K.; Bondlela, M.; Falck, J. R.; Campbell, W. B. 14,15-Epoxyeicosa-5(Z)-Enoic Acid: A Selective Epoxyeicosatrienoic Acid Antagonist That Inhibits Endothelium-Dependent Hyperpolarization and Relaxation in Coronary Arteries Circ. Res. 2002, 90, 1028-1036
60. Pratt, P. F.; Falck, J. R.; Reddy, K. M.; Kurian, J. B.; Campbell, W. B. 20-HETE Relaxes Bovine Coronary Arteries Through the Release of Prostacyclin Hypertension 1998, 31, 237-241
61. Beetham, J. K.; Tian, T.; Hammock, B. D. cDNA Cloning and Expression of a Soluble Epoxide Hydrolase from Human Liver Arch. Biochem. Biophys. 1993, 305, 197-201
62. Wixtrom, R. N.; Silva, M. H.; Hammock, B. D. Affinity Purification of Cytosolic Epoxide Hydrolase using Derivatized Epoxy-Activated Sepharose Gels Anal. Biochem. 1988, 169, 71-80
63. Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, P.; Hock, B.; Hammock, B. D. Fluorescent Substrates for Soluble Epoxide Hydrolase and Application to Inhibition Studies Anal. Biochem. 2005, 343, 66-75